What’s Next For Antacid/Analgesic OTCs After Negative US FDA Panel?
This article was originally published in The Pink Sheet
Executive Summary
Nonprescription Drug and the Drug Safety and Risk Management advisory committees jointly vote 15-5 that combining antacid with aspirin, acetaminophen or other analgesic ingredients is not a combination that should be allowed under an OTC monograph.
You may also be interested in...
US FDA Serves One Antacid/Analgesic Question For AdComm, Opens Tap On Hangover Discussion
Presentations at the US nonprescription drugs/drug safety joint advisory committee meeting will come from Bayer, marketer of the OTC brand synonymous with antacid/aspirin formulations, Alka-Seltzer, and from a firm that markets Blowfish, a caffeine/aspirin OTC indicated as a hangover remedy.
Safety Review For Upset Stomach, Hangover OTCs Reconsiders Science
The US Nonprescription Drugs and Drug Safety and Risk Management advisory committees will discuss the safety of using OTC analgesic combination products for upset stomach and hangover even though Drug Facts labels already warn about the risk of serious bleeding.
OTC Antacid/Aspirin Bleeding Risk Raises Concerns At CDER
CDER publishes a Drug Safety Communication, a consumer announcement and a MedWatch notice warning about the risk of serious bleeding when using OTC aspirin-containing antacid products.